Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia-Reference-Cited by-同舟云学术

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

Published:2019-05-28 Issue:5 Volume:14 Page:e0217303
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Evdoshenko Evgeniy^ORCID,Stepanova Alexandra,Shumilina Maria,Davydovskaya Maria,Khachanova Natalia,Neofidov Nikolay^ORCID,Kalinin Ivan,Popova Ekaterina,Dubchenko Ekaterina,Pozhidaeva Natalia,Volkov Andrey,Sivertseva Stella^ORCID,Prilenskaya Anna,Malkova Nadezhda,Korobko Denis,Vergunova Ilona,Shchur Sergey,Makshakov Gleb

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference13 articles.

1. Budget impact analysis of teriflunomide (aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of RF federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients;E. Evdoshenko;Pharmacoeconomics: theory and practice,2016

2. Health-related quality of life in multiple sclerosis: effects of natalizumab;R. Rudick;Annals of Neurology,2007

3. Давыдовская М.В. План управления рисками при терапии натализумабом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111:2:105–109

4. A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis;A. Boyko;Zhurnal nevrologii i psikhiatrii im,2015

5. Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab;M. Davydovskaya;Zhurnal nevrologii i psikhiatrii im,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-12

2. Serum levels of IgM to phosphatidylcholine predict the response of multiple sclerosis patients to natalizumab or IFN-β;Scientific Reports;2022-08-03

3. Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study ‘TOPICS greece’;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2021-07

4. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study;Journal of Neurology;2021-06-28

5. Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry;Journal of Neurology;2021-04-22